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CHILDHOOD AND ADOLESCENT HODGKIN’S LYMPHOMA
Hodgkin’s lymphoma (HL) is the third most common
malignancy in children younger than 15 years old but the
most common cancer in adolescents aged 15 to 19 years [1].
According to the World Health Organization classiﬁcation,
HL is subdivided into a classical variant, including four
subtypes (nodular sclerosing, mixed cellularity, lymphocyte
depleted, and lymphocyte rich) and characterized by the
presence of Reed-Sternberg cells, and a nodular lymphocyte
predominant variant, characterized by the presence of
lymphocyte and histocytic cells [1]. In general, the prognosis
is excellent for children and adolescents with newly diag-
nosed HL. Depending on stage, symptoms, risk groups, and
age, the estimated 5-year overall survival (OS) ranges from
80% to 95% in children and adolescents with newly diag-
nosed HL [1]. However, children and adolescents with
relapsed/refractory HL after combined modality of chemo-
therapy and radiation therapy have a worse prognosis, often
requiring reinduction therapy followed by some form of
stem cell transplantation (SCT) [2].
Autologous SCT in Children and Adolescents with
Recurrent/Relapsed HL
Myeloablative therapy followed by autologous SCT is
considered the standard of care in children and adolescents
with HL who have recurrent and/or relapsed disease [2].
Prognostic factors include chemoresponsiveness at relapse,
disease status at relapse, and performance status at relapse
[3]. The most recent prospective trial performed by the
Children’s Oncology Group analyzed children and adoles-
cents with HL at relapse or progression and determined their
event-free survival (EFS) at the time of reinduction and
through an autologous SCT after cyclophosphomide, BCNU,
and VP-16 conditioning [4]. In this study Harris et al.
demonstrated a 45% 2-year EFS in children and adolescents
with recurrent/relapsed HL after myeloablative therapy and
autologous SCT. These most recent results suggest that
autologous SCT is not curative in all children and adolescentsFinancial disclosure: See Acknowledgments on S42.
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Is There a Graft versus HL Effect after Allogeneic SCT?
Jones et al. ﬁrst demonstrated a graft versus lymphoma
effect in patients with recurrent/refractory HL [5]. There was
a 24% increase in the relapse rate after autologous versus
allogeneic SCT (allo-SCT) in patients with recurrent/refrac-
tory HL [5]. Carella et al. subsequently demonstrated the
success of autologous SCT followed by reduced-intensity
conditioning (RIC) and allo-SCT in patients with recurrent/
refractory HL [6]. More recently, Peggs et al. demonstrated
a signiﬁcant graft versus HL effect after RIC and allo-SCT in
49 adults with multiply relapsed HL (4-year OS and
progression-free survival was 55.7% and 39.0%, respectively)
[7]. Furthermore, the risk of relapse in these allo-SCT recip-
ients with either acute grade II to IV or extensive chronic
graft-versus-host disease (GVHD) was only 20.2% (95%
conﬁdence interval [CI], 5.9% to 69.6%) versus 50.7% (95% CI,
35.4% to 72.4%) in those without acute or limited chronic
GVHD (Figure 1) [7].
Sureda et al. compared RIC versus myeloablative condi-
tioning before allo-SCT in patients with relapsed/refractory
HL [8]. In this European Group for Blood and Marrow
Transplantation (EBMT) analysis, Sureda et al. demonstrated
a signiﬁcant reduction in nonrelapsed mortality in the group
receiving RIC (hazard ratio, 2.85 [95% CI, 1.62 to 5.02],
P < .001) [8]. Additionally, OS was signiﬁcantly improved in
the RIC versus myeloablative group [8] (hazard ratio, 2.05
[95% CI, 1.27 to 3.29], P < .04). Similarly, Peggs et al. most
recently demonstrated a durable salvage rate after donor
lymphocyte infusions to improve mixed donor chimerism in
patients with relapsed HL after in vivo T-cell depletion with
alemtuzumab followed by allo-SCT [9].
Allo-SCT in Children and Adolescents with HL
There are very few reports of large cohorts of children and
adolescents with recurrent/relapsed HL receiving allo-SCT
[1,2]. Claviez et al. analyzed 91 children and adolescents
with relapsed or refractory HL that underwent allo-SCT that
were registered in the EBMT registry [10]. Within this cohort,
51 children and adolescents received RIC and the remaining
40 patients received myeloablative conditioning. The 2- and
5-year OS rates were 54%  6% and 45%  6%, respectively.
Most importantly, the subset of patients transplanted in the
more recent period who had good performance status and
chemosensitive disease had a 3-year progression-free
survival andOS of 60% 27% and 83% 15%, respectively [10].
Transplantation.
Figure 1. Cumulative incidences of relapse GVHD. Cumulative-relapse inci-
dence for patients with HL after RIC acute grade IIeIV or extensive chronic
GVHD (20.2% [95% CI, 5.9%-69.6%]) versus those with no GVHD or with only
grade I acute or limited chronic GVHD (50.7% [35.4%-72.4%]). (Reprinted from
Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-
Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation.
Lancet 2005; 365:1934-41. Copyright (2005), with permission from Elsevier.)
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in children and adolescents with recurrent/refractory HL
[11]. Ten patients, median age 18.4 years, with high-risk
recurrent/refractory HL received a myeloablative condi-
tioning with cyclophosphamide, BCNU and VP16 (etoposide)
as reported by Harris et al. [4] followed by a RIC with 2 days
of busulfan and 5 days of ﬂudarabine followed by an allo-SCT
[11]. The probability of grade II to IV acute GVHD was 37.5%
(95% CI, 0 to 63%) and probability of 2-year OSwas 70% in this
ultra-high-risk group of children and adolescents [11].
Future Roles of allo-SCT in Children and Adolescents with
Recurrent/Relapsed HL
Prospective studies are needed to determine the safety
and efﬁcacy of allo-SCT in children and adolescents with
recurrent/relapsed HL. Besides the patients who relapse after
an autologous SCT, we need to determine which patients
who have the poorest risk at relapse will beneﬁt from an
allogeneic versus autologous SCT. It has yet to be determined
whether there is a subgroup of children who may beneﬁt
from an allo-SCT at the time of ﬁrst relapse or progression.
We also need to determine the role of RIC versus myeloa-
blative conditioning before allo-SCT in children and adoles-
cents with relapsed/refractory HL.
There is also a need to investigate the role of additional
allogeneic cellular therapy after an allo-SCT in patients with
recurrent/relapsed HL. Because donor lymphocyte infusion
has had some promising results but is associated with a high
risk of acute GVHD, other targeted allogeneic cellular thera-
pies are needed. In this regard, Catherine Bollard, MD, and
Mitchell S. Cairo, MD, have developed an eight-center
“Childhood, Adolescent and Young Adult Lymphoma Cell
Therapy Consortium” (Figure 2A). Because Epstein-Barr virus
infection is present in up to 40% of patients with HL, targeting
Epstein-Barr virus proteins may be a potential cellular ther-
apeutic strategy.Wehave therefore developed a newprotocol
of RIC followed by Epstein-Barr virusepositive matched
related or unrelated donor allo-SCT in children, adolescents,
and young adultswith Epstein-Barr virusepositive recurrent/
refractory HL who have failed an autologous SCT. After RIC
and allo-SCT, these patients will also receive donor-derived
latent membrane protein-cytotoxic T lymphocytes fromtheir Epstein-Barr virusepositive donor under IND no. 15104
and clinicaltrials.gov no. NCT01636388 (Figure 2B). The
results of this prospective study will determine the safety
and efﬁcacy of RIC and allo-SCT in this relapsed/recurrent
HL patient group and the safety and efﬁcacy of donor-derived
latent membrane protein-cytotoxic T lymphocyte infusions.
There is a need for other prospective RIC allo-SCT trials
in children and adolescents with recurrent/relapsed poor-
risk HL.RECURRENT/REFRACTORY ANAPLASTIC LARGE CELL
LYMPHOMA IN CHILDREN AND ADOLESCENTS:
AUTOLOGOUS, ALLOGENEIC, OR NO SCT?
ALK-positive anaplastic large cell lymphoma (ALCL)
accounts for 10% to 15% of pediatric and adolescent non-
Hodgkin lymphomas (NHLs). ALCL are characterized by
a high incidence of B-symptoms and extranodal involve-
ment. The relapse rate is 25% to 35% with current ﬁrst-line
strategies often based on short-pulse chemotherapy courses.
Available data on patients with relapse of an ALCL are
until now limited to retrospective analyses. Children and
adolescents with ALCL who relapse have a 30% to 60% chance
to reach a second continuous remission with relapse thera-
pies as different as maintenance treatment with vinblastine,
autologous SCT, or allo-SCT [12]. Considering the general
efﬁcacy of these highly variable relapse therapies, identiﬁ-
cation of risk factors for further relapse and death is critical
to allow for treatment stratiﬁcation upon relapse.Risk Factors
The time from initial diagnosis to relapse or progression
has been described as a major risk factor in children and
adolescents with relapsed ALCL [12,13]. In a French series of
41 children and adolescents, 24 patients relapsing within
12 months after diagnosis had a signiﬁcantly lower disease-
free survival compared with 17 patients with later relapses
(28% and 68%, respectively, P ¼ .01) [12]. A prognostic impact
of the time of relapse was not replicated in a series of
26 relapse patients reported from Japan [14]. In a Berlin-
Frankfurt-Muenster (BFM) group report on 74 ALCL-relapse
patients with comparable ﬁrst-line therapy and recom-
mended consolidation with autologous SCT, survival again
correlated with time of relapse. Only 4 of 16 patients
(25%  11%) with progression during initial therapy survived
compared with 38 of 58 patients with later relapses
(66%  6%; P ¼ .002) [13]. Among patients with progression
during ﬁrst-line therapy, survivors have only been reported
after allo-SCT with very few exceptions [13,15-19].
Approximately 15% of children and adolescents present
with clinically advanced dissemination in relapse docu-
mented by bone marrow or central nervous system involve-
ment [12,13], which correlated with reduced survival in one
analysis [13]. Expression of the T-cell antigen CD3 was asso-
ciated with a high risk of failure among patients consolidated
by autologous SCT in the retrospective BFM series [13]. Only 1
of 11 childrenwith relapseof a CD3-positiveALCL remained in
remission after autologous SCT, whereas 9 of 10 CD3-positive
patients who received an allo-SCT for primary or further
relapse survived. The prognostic impact of CD3 positivity,
however, needs to be interpreted cautiously because of low
patient numbers and CD3 expression data taken retrospec-
tively frompathology reports. Based on these data, patients in
theprospectiveALCL relapse trial of theEuropean Inter-Group
for Childhood Non-Hodgkin Lymphoma (EICNHL) are
Figure 2A. Lymphoma Cell Therapy Consortium. Geographic map of core sites and collaborating centers.
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to the immunophenotype.
Therapeutic Approaches
The efﬁcacy of the various consolidation therapiesd
chemotherapy, long-term low-dose consolidation, autolo-
gous SCT, and allo-SCTdfor relapsed ALK-positive ALCL
cannot be compared between and within reported studies
due to selection bias in patients receiving SCT and the retro-
spective nature of the studies [12]. The French group reported
long-term survival of ALCL relapse patients with 12 monthsFigure 2B. Treatment schema: RIC and allo-SCT followed by latent membrane protein
positive refractory/recurrent HL.CVAchemotherapy (CCNU, vinblastine, cytosine-arabinoside)
and long-term vinblastine monotherapy [12]. They recently
updated their experience on single-drug vinblastine for 36
ALCL relapse patients [20]. More than 80% of patients reached
a complete remission. Of the 25 children who received
vinblastine alone for amedian of 14months, 9 stayed in long-
term remission. A further seven patients were again treated
with weekly vinblastine in re-relapse for at least 2 years of
whom six survived long term. The patients were not a selec-
tion of good-risk relapse patients as 15 patients had re-
relapsed after autologous SCT and several patients-cytotoxic T lymphocytes (LMP-CTLs) in Patients with Epstein-Barr virus (EBV)-
Figure 3. Schema of pretargeted RIT approach. Ab-SA conjugate followed by
clearing agent before infusion of therapeutic radiolabeled biotin.
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vinblastine monotherapy for 24 months was chosen as
therapy forpatientswitha lateﬁrst relapse in theALCL relapse
trial of the EICNHL.
In the French series autologous SCT was not associated
with a higher disease-free survival compared with CVA
chemotherapy (45% versus 52%, respectively, P ¼ .55) [12].
Interpretation is complicated because 14 of 15 patients who
were consolidated by autologous SCT experienced their
relapse after current intensive ﬁrst-line therapy compared
with only 3 of 21 who did not. Among 26 Japanese relapse
patients, the rate of second relapses also was not different
between thosewho received chemotherapy (relapses 3 of 10)
or autologous SCT (relapses 3 of 8) [14]. The efﬁcacy of
autologous SCT varied widely between retrospective anal-
yses with EFS rates between <30% and almost 60% in re-
ported series [12,13,15,21]. This variation may be explained
by different approaches to ALCL relapse and variable condi-
tioning regimens. In most groups the decision for the type of
consolidation was individually based, and those who got an
autologous SCT were rather high-risk patients. In the BFM
group, autologous SCT was recommended consolidation for
all relapsed patients from 1990. Therefore, 39 of 74 relapse
patients who reached autologous SCT constituted a selection
of good-risk relapse patients [13]. The efﬁcacy of autologous
SCT was therefore tested for patients with a medium risk of
relapse in the ALCL relapse trial.
Data on the use of allo-SCT for relapsed ALCL are limited
to the Japanese and BFM series as well as an Center for
International Blood and Marrow Transplant Research
(CIBMTR) analysis (together, 38 patients) and case reports
[14,16,21,22]. Taken together, there is a very low further
relapse rate after allo-SCT for relapsed ALCL (0 to 20%),
raising the possibility that a graft-versus-lymphoma effect
may exist for this disease. The failure rate does not seem to
be associated with donor type [16]. The conditioning regi-
mens for allo-SCT predominantly used 12 Gy total body
irradiation. Therefore, it is not possible to draw any deﬁnitive
conclusions regarding the type of preparative regimen that is
most beneﬁcial for this disease. Nevertheless, the high efﬁ-
cacy of allo-SCT was the basis to choose allo-SCT for
consolidation of high-risk relapse patients in the ALCL
relapse study.
ALCL Relapse Trial and Future Prospective
The ﬁrst prospective ALCL relapse trial of the EICNHL
started in 2004 (NCT00317408). Stratiﬁcation is based on the
time of relapse followed by the expression of CD3. The
primary objectives are: (1) to improve probability of EFS for
patients with progression during ﬁrst-line therapy or relapse
of a CD3-positive ALCL by allo-SCT, (2) to test the efﬁcacy of
carmustine, etoposide, cytarabine, melphalan (BEAM),
conditioning and autologous SCT for patients with CD3-negative ALCL after ﬁrst-line therapy, and (3) to test the
efﬁcacy of weekly vinblastine monotherapy for 2 years for
patients with late relapse of a CD3-negative ALCL. Results of
an interim analysis after inclusion of 90 patients are
presented.
Brentuximab vedotin and crizotinib are new targeted
treatment options emerging for CD30-positive and ALK-
positive malignancies [23,24]. Initial data regarding the
safety proﬁle and response rates are promising. However,
given the high response rate and efﬁcacy of vinblastine
monotherapy for relapsed ALCL almost without risk of late
effects, clinical trials are necessary to deﬁne the role of these
new agents in the therapeutic management for ALCL.
NOVEL RADIOIMMUNOTHERAPY CONDITIONING
BEFORE HEMATOPOIETIC CELL TRANSPLANTATION IN
PATIENTS WITH RECURRENT/REFRACTORY LYMPHOMA
A fraction of relapsed pediatric patients may have
a signiﬁcant improvement in survival after hematopoietic
SCT (HSCT); however, high-dose therapy and HSCT may still
result in disease recurrence. One approach to reduce relapse
has focused on attempts to intensify the preparative regimen
before HSCT. This approach, in general, has been limited by
associated toxicities due to the nonspeciﬁc nature of most
conditioning agents. To overcome this limitation, radio-
labeled antibodies (Ab) have been investigated to deliver
targeted therapy to decrease the risk of relapse after HSCT.
Radionuclide-conjugated Abs appear particularly attractive
for lymphoma therapy for pediatric and adolescent patients
because (1) their surface antigens are well delineated, (2)
multiple high-quality Abs are available, (3) the best results of
clinical trials with unmodiﬁed Abs and with radiolabeled
Abs have been observed with hematologic malignancies, and
(4) lymphomas are exquisitely sensitive to radiation therapy.
Thus, varieties of novel HSCT strategies using RIT before
HSCT in pediatric patients with recurrent/refractory
lymphoma warrant continued investigation.
Radioimmunotherapy and Autologous HSCT
Non-myeloablative approaches before autologous SCT
that combine a radiolabeled anti-CD20 Ab with a condi-
tioning regimen was recently examined in a randomized
study using 90Y-ibritumomab tiuxetan combined with BEAM
chemotherapy versus BEAM alone before autologous SCT for
adult NHL patients [25]. After 2 years of follow-up, the
progression-free survival was approximately 25% better for
the patients who received both 90Y-ibritumomab tiuxetan
and BEAM chemotherapy instead of BEAM alone (49% versus
33% for high-risk patients). Although this approach was
proven to be feasible, the question remains whether adding
the radiolabeled Ab can provide signiﬁcant beneﬁt over the
use of standard high-dose chemotherapy alone in pediatric
patients. The problem of relapse in adult and pediatric NHL
patients has led investigators to explore the use of escalated
doses of a radiolabeled Ab combined with autologous SCT.
Early single-agent studies with escalated-doses of radio-
labeled Ab delivered very promising tumor-to-whole-body
ratios of at least 10:1 [3,20,26]. A nonrandomized analysis
suggested that myeloablative doses of targeted radiation as
part of the HSCTconditioning regimenmay lead to signiﬁcant
improvement in OS compared with total body irradiation for
those with advanced NHL, including pediatric patients.
Safety and feasibility trials for the treatment of primarily
pediatric and adolescent patients with advanced HL have
also been performed using anti-ferritin (an HL-associated
M.S. Cairo et al. / Biol Blood Marrow Transplant 19 (2013) S38eS43S42antigen) immunoglobulin radiolabeled at myeloablative
doses with 90Y, delivered either as stand-alone treatment or
in combination with high-dose chemotherapy, followed by
autologous marrow support. Despite results suggesting that
an HSCT approach using 90Y-anti-ferritin alone provides
objective responses in approximately half of patients with
chemotherapy-refractory disease, most survivors studied
developed HL recurrence [27].
Radioimmunotherapy and allo-SCT Approaches
Allo-SCT still may not be particularly effective in pediatric
patients with high-risk lymphoma features, such as seen in
those with rapidly growing disease, bulky lymphoma, or
multiple-relapsed disease with either chemotherapy-
resistant or chemotherapy-refractory NHL. Standard doses
of 90Y-ibritumomab tiuxetan have been added before
a reduced-intensity allo-SCT conditioning regimen using
ﬂudarabine and 200 cGy of total body irradiation [28].
This strategy was well tolerated, as the 100-day nonrelapse
mortality rate was <5% and this primarily adult advanced
NHL patient population had an encouraging OS rate of 31% at
a median follow-up of 30 months after HSCT. Current
approaches using up to four times the standard dose
of 90Y-ibritumomab tiuxetan for adult and pediatric patients
with relapsed NHL who need additional measures to control
aggressive disease are ongoing.
New Directions for Targeted Radiation Delivery and HSCT
Alternative antigenic targets
Although the most widely used target to date remains
CD20, preclinical data indicate that CD20 blocking may
impair the ability to target CD20 with RIT [29]. One alter-
native is to circumvent the potential of CD20 blocking (and
the exclusion of CD20-negative NHL histologies) by targeting
alternate targets such as the pan-hematopoietic antigen
CD45. Preclinical and clinical data using radiolabeled anti-
CD45 Ab support this strategy for continuing human
studies [29].
Alternative radionuclides
RIT has primarily used beta-emitting radionuclides
(particularly 131I and 90Y) for the treatment of lymphomas.
Relapses in NHL studies may be due, however, to the low
energy transfer characteristics of beta particles, resulting in
suboptimal killing of tumor cells, and the long path length of
the beta particle may lead to dose-limiting toxicities as it
circulates in the bloodstream. An attractive alternative might
use an alpha-emitter because their radiobiologic properties
may be more suited for HSCT of lymphoma (ie, conditioning
and treatment of minimal residual disease) than a beta-
emitter. The alpha-emitting radionuclides exhibit very high
cytotoxicity due to the release of large amounts of energy in
a linear fashion within a few cell diameters (w50 to 90 mm).
Clinical investigations using alpha-emitters with favorable
radiobiologic characteristics are continuing; however, other
issues such as cost, availability, labeling chemistry, and
in vivo stability have impacted their use in RIT.
Nanoparticle delivery platforms for RIT
Increased attention has been placed on nanomaterials
because the nanostructured surfaces offer a large surface
area and greater reactivity, making nanovectors potentially
ideal for targeted RIT. The characteristics necessary for
a successful carrier nanoparticle are that it should (1) be
targeted for delivery of its payload, (2) have a sufﬁcient
contact time with the target, and (3) not be removed by thereticuloendothelial system so that toxic levels of radio-
particles are not accumulated in the liver and spleen [30].
A number of studies to determine the efﬁcacy of nanoparticle
"carriers" for radiopharmaceutical delivery have shown
many factors that determine circulation time and clearance;
these factors include nanoparticle size, surface coating and
surface charge, presence of high immunologic protein
concentration on the particle surface, as well as particle size
[30,31].
Pretargeted RIT
Many groups have explored a pretargeted RIT approach as
a mechanism to further boost targeted radiation doses while
minimizing nonspeciﬁc radiation exposure to normal organs.
In one pretargeted RIT strategy, the targeting Ab can be
conjugated to streptavidin (SA) in an attempt to uncouple the
delivery of the Ab from the delivery of the radiation [32].
The Ab-SA conjugate, delivered as an unlabeled agent, can
be allowed to localize to hematologic targets over 24 to
48 hours. Unbound Ab-SA may be then cleared from the
circulation by way of Ashwell receptors in the liver using
a biotinylated clearing agent before a therapeutic dose of
radiobiotin. In this model, the biotin moiety can be conju-
gated to a radiometal via a 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) chelate. Radiobiotin can
subsequently localize rapidly to the Ab-SA conjugate pre-
targeted to malignant cells. Unbound radiobiotin can be
rapidly eliminated through the kidneys into the urine,
further reducing prolonged exposure of free radionuclide in
normal organ tissues (Figure 3). Variations of this approach
have also been explored to further optimize pretargeted RIT,
including the development of bispeciﬁc Ab fragments where
one arm of the single chain is engineered for its speciﬁc
target, which may improve on the current pretargeted
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